Arrowhead Research ARWR Return on equity

Return on equity at other companies

Ionis PharmaceuticalsIONS

-105.5%+336pp

ALN

Alnylam PharmaceuticalsALNY

91.4%—

Assembly BiosciencesASMB

-36.9%-15.1pp

Arbutus Biopharma CorporationABUS

94.7%+65.1pp

Ultragenyx PharmaceuticalRARE

-325.6%+36.9pp

Beam TherapeuticsBEAM

-47.1%—

FAQ

What is Arrowhead Research's return on equity?

Arrowhead Research (ARWR) reported return on equity of -46.4% in Q1 2026.

How has Arrowhead Research's return on equity changed year-over-year?

Arrowhead Research's return on equity decreased by 88.0% year-over-year, from -24.7% to -46.4%.

What is the long-term trend for Arrowhead Research's return on equity?

Over 4 years (2021 to 2025), Arrowhead Research's return on equity has grown at a -64.7% compound annual growth rate (CAGR), from -32.4% to -0.5%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.